Eli Lilly’s Dan Skovronsky on oral GLP-1, ‘slower ramp’ for Alzheimer’s and deals on ‘underappreciated’ assets

Dan Skovronsky knows that any conversation about Eli Lilly is going to be largely about its work in obesity and Alzheimer’s. Although he wants everyone to know that the company is also excited about candidates in immunology and oncology, he’s also ready to take questions about those hottest topics head-on.

Speaking at an investor conference organized by Evercore ISI, Skovronsky — whose string of titles at Lilly includes executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories — addressed both high-level and granular questions about the pipeline and strategy.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。